![Erez Chimovits](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erez Chimovits
Président chez
ADARX PHARMACEUTICALS, INC.
Fortune : - $ au 31/10/2026
Profil
Mr. Erez Chimovits is an Independent Director at Braveheart Bio, Inc., an Independent Director at Upstream Bio, Inc., a Chairman at ADARx Pharmaceuticals, Inc., a Partner at OrbiMed Israel Partners LP, a Partner at OrbiMed Advisors Private Equity and a Senior Managing Director at OrbiMed Capital LLC.
He is on the Board of Directors at Braveheart Bio, Inc., Upstream Bio, Inc., Nucleix Ltd., Galecto Biotech ApS, FutuRx Ltd., Capstan Therapeutics, Inc., Emendo Biotherapeutics, Inc., Fore Biotherapeutics, Inc., ImmPACT Bio USA, Inc. and MiroBio Ltd. Mr. Chimovits was previously employed as an Independent Director by Novus Therapeutics, Inc., an Independent Director by LogicBio Therapeutics, Inc., an Independent Director by BiomX, Inc., a Chief Executive Officer by Therapix Biosciences Ltd., a President & Executive VP-Commercial Operations by Compugen USA, Inc., a President by Compugen Ltd., an Executive Vice President-Commercial Operations by Compugen, Inc. (United States), and a Chairman by Otic Pharma Ltd. He also served on the board at resTORbio, Inc., Damora Therapeutics, Inc., Adicet Bio, Inc., BiomX Ltd., Xylo Technologies Ltd., Adicet Therapeutics, Inc., Atox Bio Ltd., Mitoconix Bio Ltd. and RDD Pharma Ltd. He received his undergraduate degree from Tel-Aviv University, a graduate degree from Tel-Aviv University and an MBA from Tel-Aviv University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
UPSTREAM BIO, INC. -.--% | 09/06/2026 | 0 ( -.--% ) | - $ | 31/10/2026 |
Postes actifs de Erez Chimovits
| Sociétés | Poste | Début |
|---|---|---|
| ADARX PHARMACEUTICALS, INC. | Président | 01/05/2020 |
| UPSTREAM BIO, INC. | Directeur/Membre du Conseil | 01/10/2021 |
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Develops, manufactures and markets non-invasive molecular cancer diagnostic tests | Directeur/Membre du Conseil | - |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Directeur/Membre du Conseil | - |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Directeur/Membre du Conseil | - |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Operates genome editing company that develops genetic medicines and cell therapies for severe diseases | Directeur/Membre du Conseil | - |
Immpact Bio USA, Inc.
 Immpact Bio USA, Inc. BiotechnologyHealth Technology Develops cell therapy for treating cancer | Directeur/Membre du Conseil | 20/01/2022 |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Manufactures galectin modulators for the treatment of severe diseases which includes fibrosis and cancer | Directeur/Membre du Conseil | 26/10/2018 |
MiroBio Ltd.
 MiroBio Ltd. BiotechnologyHealth Technology Develops therapeutics for auto-immune diseases | Directeur/Membre du Conseil | 21/06/2022 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Erez Chimovits
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Erez Chimovits
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
72
Relations au 1er degré
31
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 31 |
|---|---|
Compugen Ltd.
 Compugen Ltd. BiotechnologyHealth Technology Discovers and researches drug & diagnostics | Health Technology |
OrbiMed Capital LLC
 OrbiMed Capital LLC Financial ConglomeratesFinance Operates as an investment firm | Finance |
OrbiMed Israel Partners LP
 OrbiMed Israel Partners LP Investment ManagersFinance Acts as Venture Capital Fund | Finance |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Xylo Technologies Ltd.
 Xylo Technologies Ltd. Information Technology ServicesTechnology Services Operates as a technology company that engages in advancing medical innovative solutions for large-scale market applications | Technology Services |
SciSparc Ltd.
 SciSparc Ltd. Pharmaceuticals: MajorHealth Technology Develops innovative vaccines and immunotherapy products | Health Technology |
RDD Pharma Ltd.
 RDD Pharma Ltd. Medical SpecialtiesHealth Technology Develops pharmacological treatments for diseases of the anorectal region | Health Technology |
Otic Pharma Ltd.
 Otic Pharma Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for ear indications | Health Technology |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Manufactures galectin modulators for the treatment of severe diseases which includes fibrosis and cancer | Health Technology |
Compugen, Inc. (United States) | |
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Develops, manufactures and markets non-invasive molecular cancer diagnostic tests | Health Services |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx invests in companies located in Israel. The firm focuses on sectors such as health technology and technology services with an investment size of ILS 3 million. It participates in seed stage transactions and also makes follow on investment. | Finance |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines and therapies for bone metabolism, cardiology, neurology and rare diseases | Health Technology |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology company that specializes in cancer therapies | Health Technology |
Eledon Pharmaceuticals, Inc.
 Eledon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
BiomX Ltd.
 BiomX Ltd. Pharmaceuticals: MajorHealth Technology Develops drugs for cancer treatment | Health Technology |
Mitoconix Bio Ltd.
 Mitoconix Bio Ltd. BiotechnologyHealth Technology Develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Operates genome editing company that develops genetic medicines and cell therapies for severe diseases | Health Technology |
MiroBio Ltd.
MiroBio Ltd. BiotechnologyHealth Technology Develops therapeutics for auto-immune diseases | Health Technology |
BiomX, Inc.
 BiomX, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops siRNA therapeutics to treat diseases | Health Technology |
Immpact Bio USA, Inc.
Immpact Bio USA, Inc. BiotechnologyHealth Technology Develops cell therapy for treating cancer | Health Technology |
Adicet Bio, Inc.
 Adicet Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development of cell immunotherapies | Health Technology |
Compugen Usa, Inc.
 Compugen Usa, Inc. Information Technology ServicesTechnology Services The company is based in San Francisco, CA. Part of Compugen Ltd., Compugen USA, Inc. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies. The company leverages a proprietary AI-powered predictive computational discovery platform called Unigen™, which integrates multi-omics, single-cell RNA sequencing, spatial omics, and machine learning to identify novel drug targets and biological pathways. This platform enables the discovery and development of immuno-oncology therapeutics aimed at patients unresponsive to existing treatments. Compugen’s pipeline features multiple antibody candidates, including COM701 (anti-PVRIG), COM902 (a high-affinity Fc-reduced anti-TIGIT antibody), GS-0321 (anti-IL18BP), and Rilvegostomig (an Fc-reduced anti-PD1/TIGIT bispecific antibody), which are advanced through clinical trials across cancer indications such as non-small-cell lung, gastrointestinal, and endometrial cancers. The company engages in strategic collaborations, including an exclusive license agreement with AstraZeneca for TIGIT-targeting antibodies and a license agreement with Gilead for anti-IL-18 binding protein antibodies. | Technology Services |
Upstream Bio, Inc.
 Upstream Bio, Inc. BiotechnologyHealth Technology Engages in developing treatments for inflammatory diseases | Health Technology |
Capstan Therapeutics, Inc.
 Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops targeted in vivo RNA technologies | Commercial Services |
